Adaptimmune, Cryoport in Three-Year Cell Therapy Supply Chain Pact

Published on: 

The collaboration aims to reduce “vein-to-vein” time for patients and to optimize manufacturing and supply operations.

On Oct. 9, 2019, Adaptimmune Therapeutics, a T-cell therapy company focused on cancer treatment, and Cryoport, a provider of temperature-controlled logistics solutions, announced a three-year agreement to ensure safe and fully monitored transport of Adaptimmune’s cell therapies.

Under the agreement, the “vein-to-vein” time for patients in clinical trials and ahead of commercialization is expected to be reduced. In addition, other solutions will contribute to the optimization of manufacturing and supply operations, including investment in the latest systems and technology, digitization of the supply chain information, and improved communications with patients and healthcare professionals.

“Rapidly and safely delivering a patient’s cells back to the hospital after the cells have been armed with our TCRs [T cell receptors] and frozen for shipment is an essential capability for us,” said John Lunger, Adaptimmune’s chief patient supply officer, in a company press release. “Control and monitoring are critical because a simple temperature variation can jeopardize these cells and, ultimately, the product we supply to patients. With Cryoport’s technology and expertise, we will be able to track the conditions, location, and handling of these cells-a key capability as we prepare to ship commercially in 2022.”

“Adaptimmune has a robust pipeline of therapies and a strong in-house manufacturing platform which makes us very pleased to be expanding and extending our relationship with them under this new, exclusive logistics agreement. Cryoport’s solution for Adaptimmune is comprehensive and relies upon our world class technologies including the SmartPak II Condition Monitoring System and the Cryoportal Logistics Management Platform. Today’s joint announcement underscores the strong relationship between our companies and highlights the growing importance of temperature-controlled logistics solutions in advancing the life sciences at large,” stated Jerrell Shelton, Cryoport CEO, in the press release.


Cryoport’s proprietary SmartPak II Condition Monitoring System provides near real-time information while tracking location, temperature, orientation, humidity, and shock as well as other factors to enable the transport of temperature-sensitive cell therapies. This information is automatically collected and retained by Cryoport’s cloud based Cryoportal Logistics Management Platform, which gives companies the ability to intervene and make corrections while a shipment is in transit.

Source: Adaptimmune Therapeutics